NASDAQ$LIVN

LivaNova PLC · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported strong revenue growth and EPS, driven by solid performance in Cardiopulmonary and Neuromodulation segments.

LivaNova reported a strong Q4 2023, with revenue increasing by 12.8% to $310.1 million and U.S. GAAP diluted earnings per share of $0.30. Adjusted diluted earnings per share was $0.87. The company provided full-year 2024 guidance, expecting revenue growth between 4% and 5% on a constant-currency basis and adjusted diluted earnings per share in the range of $2.95 to $3.05.

  • Fourth-quarter revenue increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis.
  • U.S. GAAP diluted earnings per share was $0.30 and adjusted diluted earnings per share was $0.87.
  • The company initiated a wind down of the Advanced Circulatory Support segment in January 2024.
  • Vladimir A. Makatsaria was named the Company's Chief Executive Officer (CEO) and member of the Board of Directors, effective March 1, 2024.

Headline financials

Total Revenue

$310M

Previous: $275M+12.8%
EPS (adj)

$0.87

Previous: $0.81+7.4%
Capital Expenditures

-$12.9M

Previous: $9.13M-241.6%
Net Income

$16.3M

Previous: $1.7M+858.8%
Operating Income

-$88M

Previous: $14M-728.6%
Gross Profit

$187M

Previous: $184M+2.1%
R&D Expense

$44.6M

No prior period
Stock-Based Comp

$8.28M

Previous: $12.3M-32.8%

Revenue & EPS history

LivaNova · Revenue · Quarterly

$310M

Q4 2023+12.8%vs Q4 2022
Beat estimate in 14 of 15 quarters(93%)
ActualEstimate

Revenue by segment

LivaNova · $265M total across 3 segments · Q4 2022

  • Cardiopulmonary
    $137M
  • Neuromodulation
    $127M
  • Other Revenue
    $1.6M

Forward guidance

LivaNova expects revenue for full-year 2024 to grow between 4 and 5 percent on a constant-currency basis. When excluding the impact of the ACS segment wind down, the Company expects revenue for full-year 2024 to grow between 6 and 7 percent on a constant-currency basis. Adjusted diluted earnings per share for 2024 are expected to be in the range of $2.95 to $3.05.

Tailwinds

  • Revenue for full-year 2024 to grow between 4 and 5 percent on a constant-currency basis.
  • Revenue for full-year 2024 to grow between 6 and 7 percent on a constant-currency basis, excluding the impact of the ACS segment wind down.
  • Foreign currency is expected to be negligible based on current exchange rates.
  • Adjusted diluted earnings per share for 2024 are expected to be in the range of $2.95 to $3.05.
  • Adjusted free cash flow will be in the range of $95 to $115 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+1.2%

Avg return

Earnings day

+0.9%

Avg return

5 days after

+1.3%

Avg return

30 days after

58%

26 / 45 earnings

Positive

+23.3%

Q1 2025

Best reaction

-19.9%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+15.1%+21.7%+25.5%
Q4 2025+0.8%+1.8%-10.4%
Q3 2025-5.8%-5.7%+17.5%
Q1 2025+23.3%+28.6%+30.7%
Q4 2024-15.8%-15.9%-20.0%
Q3 2024-2.5%-7.5%-0.9%
Q2 2024-5.8%-11.8%-1.8%
Q1 2024+12.9%+12.3%+9.5%
Q4 2023+6.9%+6.4%+6.4%
Q3 2023-0.8%-0.9%-6.4%
Q2 2023+7.0%+9.1%+4.0%
Q1 2023+0.6%-0.0%-0.6%
Q4 2022-9.6%-12.1%-23.6%
Q3 2022+2.2%+6.6%+19.1%
Q2 2022-3.0%-2.2%-13.9%
Q1 2022-13.2%-21.8%-9.1%
Q4 2021+7.9%+9.4%+8.6%
Q3 2021+15.3%+15.9%+2.4%
Q2 2021+8.0%+7.1%+1.1%
Q1 2021+3.8%+1.4%+0.8%
Q4 2020+3.5%+3.6%+2.6%
Q3 2020+1.0%-4.5%+8.9%
Q2 2020-11.0%-17.2%-14.9%
Q1 2020-5.8%-10.4%-5.1%
Q4 2019+3.3%+5.2%-34.6%
Q3 2019-6.8%-6.4%+10.4%
Q2 2019+5.8%+1.7%+2.5%
Q1 2019+5.2%+8.8%+4.4%
Q4 2018-4.2%-3.1%+0.0%
Q3 2018+5.6%+6.9%-6.6%
Q2 2018+12.2%+10.3%+14.0%
Q1 2018-8.0%-6.7%+5.9%
Q4 2017+2.4%+0.8%+1.1%
Q3 2017+11.7%+9.1%+20.3%
Q2 2017+1.4%+1.5%+7.7%
Q1 2017+4.0%+4.8%+7.0%
Q4 2016+4.2%-2.0%-2.8%
Q3 2016-19.9%-21.0%-19.3%
Q2 2016+14.9%+11.1%+12.0%
Q1 2016-3.5%
Q4 2014-0.0%
Q4 2013-0.0%
Q4 2015-1.1%
Q2 2015+1.9%
Q3 2015-10.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro